Form 13-F position report

ELEVATION ONCOLOGY INC

Reported by MORGAN STANLEY

ELEV CUSIP 28623U101 Manager CIK 0000895421

Reported 0 shares, down 16,608 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 17 Through Q3 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 48000
2022-03-31 16000
2022-06-30 0
2022-09-30 0
2022-12-31 109
2023-03-31 282055
2023-06-30 5209
2023-09-30 2271
2023-12-31 1840
2024-03-31 144010
2024-06-30 3438620
2024-09-30 570559
2024-12-31 236537
2025-03-31 23084
2025-06-30 6097
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for ELEVATION ONCOLOGY INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -16,608 (-100.0%) 0 $0 2025-11-14
Q2 2025 Reduced 16,608 -72,487 (-81.4%) < 0.01% $6,097 2025-08-15
Q1 2025 Reduced 89,095 -331,342 (-78.8%) < 0.01% $23,084 2025-05-15
Q4 2024 Reduced 420,437 -530,652 (-55.8%) < 0.01% $236,537 2025-02-14
Q3 2024 Reduced 951,089 -322,474 (-25.3%) < 0.01% $570,559 2024-11-14
Q2 2024 Added 1,273,563 +1,245,491 (4436.8%) < 0.01% $3,438,620 2024-08-14
Q1 2024 Added 28,072 +24,645 (719.1%) < 0.01% $144,010 2024-05-15
Q4 2023 Unchanged 3,427 0 (0.0%) < 0.01% $1,840 2024-02-13
Q3 2023 Unchanged 3,427 0 (0.0%) < 0.01% $2,271 2023-11-15
Q2 2023 Reduced 3,427 -145,023 (-97.7%) < 0.01% $5,209 2023-08-14
Q1 2023 Added 148,450 +148,335 (128987.0%) < 0.01% $282,055 2023-05-15
Q4 2022 Unchanged 115 0 (0.0%) < 0.01% $109 2023-02-14
Q3 2022 Unchanged 115 0 (0.0%) 0 $0 2022-11-14
Q2 2022 Reduced 115 -6,224 (-98.2%) 0 $0 2022-08-15
Q1 2022 Reduced 6,339 -1,566 (-19.8%) < 0.01% $16,000 2022-05-13
Q4 2021 Added 7,905 +6,325 (400.3%) < 0.01% $48,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

64 managers reported ELEVATION ONCOLOGY INC for Q3 2025.

Managers reporting ELEVATION ONCOLOGY INC in Q3 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ADVISOR GROUP HOLDINGS INC Unchanged 2,000 0 < 0.01% $720 9 qtrs
GROUP ONE TRADING L P Reduced 0 -118 0 $0 5 qtrs
Persistent Asset Partners Ltd Reduced 0 -83,416 0 $0 2 qtrs
Essential Partners LLC Reduced 0 -24 0 $0 2 qtrs
MARSHALL WACE LLP Reduced 0 -154,793 0 $0 2 qtrs
TWO SIGMA SECURITIES LLC Reduced 0 -12,717 0 $0 4 qtrs
DELTEC ASSET MANAGEMENT LLC Reduced 0 -1,436,363 0 $0 2 qtrs
FNY Investment Advisers LLC Reduced 0 -10,000 0 $0 2 qtrs
ExodusPoint Capital Management LP Reduced 0 -597,017 0 $0 2 qtrs
Exome Asset Management LLC Reduced 0 -110,353 0 $0 2 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2025
Filed
November 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.